Periostin, a matrix protein, has potential as a novel serodiagnostic marker for cholangiocarcinoma.

Differentiating intrahepatic cholangiocarcinoma (CCA) from other hepatic malignancies is crucial in deciding on treatment modalities and predicting clinical outcomes in patients. Periostin is a secreted protein from stromal cells and regulates the development of cancer cells through interaction with the extracellular matrix. Given that proliferation of fibrous stromal cells is a pathological feature of CCA, we examined the potential use of periostin as a serodiagnostic marker for this disease. Our study enrolled a total of 79 patients including liver cirrhosis (n=26), hepatocellular carcinoma (HCC, n=24), CCA (n=8), other hepatic malignancies (n=13) and histologically normal livers (normal control, n=8). Periostin expression was evaluated using immunohistochemistry and serum periostin level was determined via enzyme-linked immunoassay. The diagnostic performance of serum periostin levels for distinguishing CCA patients from others was also assessed. Strong expression of periostin was noted only in the fibrous stroma of CCA tissue. Serum periostin levels (median) were significantly higher in patients with CCA (513 ng/ml) compared to those patients with normal liver, liver cirrhosis, HCC and other malignancies (120, 146, 155, 213 ng/ml, respectively, all P<0.05). The area under receiver operating characteristics curve of serum periostin level was 0.94 [95% confidence interval (CI), 0.85-1.00, P<0.001]. With optimal cut-off value of 302 ng/ml, diagnostic performances for CCA were as follows: sensitivity, 0.88 (95% CI, 0.47-0.99); specificity, 0.92 (0.83-0.96); accuracy, 0.91 (0.83-0.96); positive predictive value, 0.54 (0.25-0.81); negative predictive value, 0.98 (0.92-0.99); positive-likelihood ratio, 10.4 (4.8-13.4); and negative-likelihood ratio, 0.13 (0.03-0.49). We demonstrated increased expression of periostin in the stroma of CCA tissue. Serum periostin levels were significantly elevated in patients with CCA and enable distinction between CCA and other hepatic malignancies.

[1]  Yasunori Sato,et al.  Epithelial-mesenchymal transition induced by transforming growth factor-{beta}1/Snail activation aggravates invasive growth of cholangiocarcinoma. , 2010, The American journal of pathology.

[2]  E. Gaudio,et al.  Cholangiocarcinoma: update and future perspectives. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[3]  Holger Moch,et al.  Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas , 2010, Histopathology.

[4]  A. Kulkarni,et al.  Current research in perineural invasion of cholangiocarcinoma , 2010, Journal of experimental & clinical cancer research : CR.

[5]  I. Kii,et al.  Interaction between Periostin and BMP-1 Promotes Proteolytic Activation of Lysyl Oxidase* , 2010, The Journal of Biological Chemistry.

[6]  Y. Abiko,et al.  Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker , 2010, Molecular Cancer.

[7]  T. Nishiyama,et al.  Incorporation of Tenascin-C into the Extracellular Matrix by Periostin Underlies an Extracellular Meshwork Architecture* , 2009, The Journal of Biological Chemistry.

[8]  R. Markwald,et al.  The many facets of the matricelluar protein periostin during cardiac development, remodeling, and pathophysiology , 2009, Journal of Cell Communication and Signaling.

[9]  S. Bao,et al.  The multifaceted role of periostin in tumorigenesis , 2009, Cellular and Molecular Life Sciences.

[10]  D. Hamilton.  Functional role of periostin in development and wound repair: implications for connective tissue disease , 2008, Journal of Cell Communication and Signaling.

[11]  F. Motoi,et al.  Periostin, secreted from stromal cells, has biphasic effect on cell migration and correlates with the epithelial to mesenchymal transition of human pancreatic cancer cells , 2008, International journal of cancer.

[12]  M. Sata,et al.  Periostin and bone marrow fibrosis , 2008, International journal of hematology.

[13]  R. Markwald,et al.  Periostin Is Required for Maturation and Extracellular Matrix Stabilization of Noncardiomyocyte Lineages of the Heart , 2008, Circulation research.

[14]  Toshio Tanaka,et al.  T helper 1 cells stimulated with ovalbumin and IL-18 induce airway hyperresponsiveness and lung fibrosis by IFN-γ and IL-13 production , 2007, Proceedings of the National Academy of Sciences.

[15]  Y. Kudo,et al.  Periostin: novel diagnostic and therapeutic target for cancer. , 2007, Histology and histopathology.

[16]  A. Ramamurthi,et al.  Periostin regulates collagen fibrillogenesis and the biomechanical properties of connective tissues , 2007, Journal of cellular biochemistry.

[17]  N R Lemoine,et al.  Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the β4 integrin and the PI3k pathway , 2007, Oncogene.

[18]  T. Kawaguchi,et al.  Clearance of HCV Improves Insulin Resistance, Beta-Cell Function, and Hepatic Expression of Insulin Receptor Substrate 1 and 2 , 2007, The American Journal of Gastroenterology.

[19]  S. Toda,et al.  Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. , 2006, The Journal of allergy and clinical immunology.

[20]  H. Pitt,et al.  Radiation therapy, chemotherapy and chemoradiation in hilar cholangiocarcinoma. , 2005, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[21]  I. Okayasu,et al.  Cellular and stromal characteristics in the scirrhous hepatocellular carcinoma: Comparison with hepatocellular carcinomas and intrahepatic cholangiocarcinomas , 2005, Pathology international.

[22]  Ryan M. Anderson,et al.  Acquired Expression of Periostin by Human Breast Cancers Promotes Tumor Angiogenesis through Up-Regulation of Vascular Endothelial Growth Factor Receptor 2 Expression , 2004, Molecular and Cellular Biology.

[23]  Ryan M. Anderson,et al.  Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. , 2004, Cancer cell.

[24]  M. Loda,et al.  Elevated Serum Periostin Levels in Patients with Bone Metastases from Breast but not Lung Cancer , 2003, Breast Cancer Research and Treatment.

[25]  H. Thomas,et al.  Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document , 2002, Gut.

[26]  D. Auclair,et al.  Serum level of the periostin, a homologue of an insect cell adhesion molecule, in thymoma patients. , 2001, Cancer letters.

[27]  D. Auclair,et al.  Serum level of the periostin, a homologue of an insect cell adhesion molecule, as a prognostic marker in nonsmall cell lung carcinomas , 2001, Cancer.

[28]  J. Lunz,et al.  Growth control of human biliary epithelial cells by interleukin 6, hepatocyte growth factor, transforming growth factor β1, and activin a: Comparison of a cholangiocarcinoma cell line with primary cultures of non‐neoplastic biliary epithelial cells , 2000, Hepatology.

[29]  T. Kawaguchi,et al.  Cholestasis with altered structure and function of hepatocyte tight junction and decreased expression of canalicular multispecific organic anion transporter in a rat model of colitis , 2000, Hepatology.

[30]  K. Tanikawa,et al.  Different lobular distributions of altered hepatocyte tight junctions in rat models of intrahepatic and extrahepatic cholestasis , 1999, Hepatology.

[31]  T. Tsuji,et al.  Transforming Growth Factor-β1 Stimulates or Inhibits Cell Growth via Down- or Up-Regulation of p21/Waf1 , 1998 .

[32]  G. Guyatt,et al.  Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. , 1994, JAMA.

[33]  J A Swets,et al.  Measuring the accuracy of diagnostic systems. , 1988, Science.

[34]  M. Sawyer,et al.  Cholangiocarcinoma: has there been any progress? , 2010, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[35]  K. Horiuchi,et al.  Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta. , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.